FDA approves VYALEV for adults living with advanced parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
Strokes are affecting approximately 1.8 million people annually
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated